SCHEMBL30980790

SCHEMBL30980790

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1CCCCCOCCOCCNC(=O)NCCOCCOCCOCCOCCOCCN=[N+]=[N-]

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.37
▸ LGALS8 O00214 1/20 0.37
▸ LGALS3 P17931 1/20 0.37
▸ LGALS4 P56470 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ MDK P21741 2/20 0.36
▸ OGA O60502 2/20 0.33
▸ CD69 Q07108 1/20 0.33
▸ PTN P21246 1/20 0.33
▸ BDNF P23560 1/20 0.33
▸ CD209 Q9NNX6 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980606 0.87 MAPK1 (0.47) MAPK1ALDH1A1LGALS8LGALS3LGALS4
SCHEMBL30980757 0.86 MAPK1 (0.46) MAPK1ALDH1A1LGALS8LGALS3LGALS4
SCHEMBL30980522 0.85 MAPK1 (0.43) MAPK1ALDH1A1LGALS8LGALS3LGALS4
SCHEMBL30980642 0.83 MAPK1 (0.43) MAPK1ALDH1A1LGALS8LGALS3LGALS4
SCHEMBL30980704 0.82 MAPK1 (0.52) MAPK1ALDH1A1LGALS8LGALS3LGALS4
SCHEMBL30980707 0.82 MAPK1 (0.43) MAPK1ALDH1A1LGALS8LGALS3LGALS4
SCHEMBL30980649 0.82 MAPK1 (0.43) MAPK1ALDH1A1LGALS8LGALS3LGALS4
SCHEMBL31384228 0.80 MAPK1 (0.46) MAPK1ALDH1A1LGALS8LGALS3LGALS4
SCHEMBL30980511 0.79 MAPK1 (0.53) MAPK1ALDH1A1LGALS8LGALS3LGALS4
SCHEMBL31384251 0.79 MAPK1 (0.53) MAPK1ALDH1A1LGALS8LGALS3LGALS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
Send feedback